The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ACCELERON PHARMA INC | COM | 00434H108 | 65,949 | 1,553,937 | SH | SOLE | 1,553,937 | 0 | 0 | ||
| AKEBIA THERAPEUTICS INC | COM | 00972D105 | 33,086 | 2,225,000 | SH | SOLE | 2,225,000 | 0 | 0 | ||
| CORVUS PHARMACEUTICALS INC | COM | 221015100 | 33,608 | 3,244,046 | SH | SOLE | 3,244,046 | 0 | 0 | ||
| CRISPR THERAPEUTICS AG | NAMEN AKT | H17182108 | 5,243 | 223,317 | SH | SOLE | 223,317 | 0 | 0 | ||
| DERMIRA INC | COM | 24983L104 | 55,185 | 1,984,364 | SH | SOLE | 1,984,364 | 0 | 0 | ||
| GLAUKOS CORP | COM | 377322102 | 4,012 | 156,429 | SH | SOLE | 156,429 | 0 | 0 | ||
| INOGEN INC | COM | 45780L104 | 422,653 | 3,549,320 | SH | SOLE | 3,549,320 | 0 | 0 | ||
| INVUITY INC | COM NEW | 46187J205 | 8,456 | 1,363,848 | SH | SOLE | 1,363,848 | 0 | 0 | ||
| MERUS N V | COM | N5749R100 | 27,362 | 1,410,417 | SH | SOLE | 1,410,417 | 0 | 0 | ||
| NABRIVA THERAPEUTICS PLC | SHS | G63637105 | 17,490 | 2,924,822 | SH | SOLE | 2,924,822 | 0 | 0 | ||
| ORTHOPEDIATRICS INC | COM | 68752L100 | 7,273 | 379,014 | SH | SOLE | 379,014 | 0 | 0 | ||
| RA PHARMACEUTICALS INC | COM | 74933V108 | 17,268 | 2,031,562 | SH | SOLE | 2,031,562 | 0 | 0 | ||
| VERONA PHARMA PLC | SPONSORED ADS | 925050106 | 8,793 | 740,740 | SH | SOLE | 740,740 | 0 | 0 | ||
| WRIGHT MED GROUP N V | RIGHT 03/01/2019 | N96617126 | 6,979 | 4,622,032 | PRN | SOLE | 0 | 0 | 4,622,032 | ||